| Jere H Weaver, MD | |
|
722 Bank St Ne, Decatur, AL 35601-1610 | |
| (256) 351-1874 | |
| (256) 351-1876 |
| Full Name | Jere H Weaver |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 722 Bank St Ne, Decatur, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265436067 | NPI | - | NPPES |
| 51025264 | Other | AL | BLUE CROSS PROVIDER NUMBE |
| 009912888 | Medicaid | AL | |
| 4585899 | Other | AL | AETNA PROVIDER NUMBER |
| 01-12771 | Other | AL | UNITED HEALTH |
| 010050478 | Other | AL | MEDICARE RAILROAD RETIREE |
| 515-97711 | Other | AL | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 11631 (Alabama) | Primary |
| Entity Name | Jere H. Weaver Md |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851573778 PECOS PAC ID: 1658321989 Enrollment ID: O20050125000607 |
News Archive
Statistics show that the number of people diagnosed with autism has increased steadily over the past 30 years resulting in a surge in the number of adults with autism graduating from high school. However, preliminary employment studies indicate that this population may earn less and be employed at a lower rate compared to other people with disabilities.
Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).
In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting‐edge treatments for this potentially deadly-and quite common-infection.
"More than 8,000 people - representatives of governments, international agencies, development partners and civil society - are attending the Fourth United Nations Conference on the Least Developed Countries (LDC-IV), outlining a plan to lessen the burden of poverty, hunger and disease on the world's most vulnerable people," Inter Press Service reports.
As the covid crisis wanes and life approaches normal across the U.S., health industry leaders and many patient advocates are pushing Congress and the Biden administration to preserve the pandemic-fueled expansion of telehealth that has transformed how millions of Americans see the doctor.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jere H Weaver, MD 722 Bank St Ne, Decatur, AL 35601-1610 Ph: (256) 351-1874 | Jere H Weaver, MD 722 Bank St Ne, Decatur, AL 35601-1610 Ph: (256) 351-1874 |
News Archive
Statistics show that the number of people diagnosed with autism has increased steadily over the past 30 years resulting in a surge in the number of adults with autism graduating from high school. However, preliminary employment studies indicate that this population may earn less and be employed at a lower rate compared to other people with disabilities.
Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).
In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting‐edge treatments for this potentially deadly-and quite common-infection.
"More than 8,000 people - representatives of governments, international agencies, development partners and civil society - are attending the Fourth United Nations Conference on the Least Developed Countries (LDC-IV), outlining a plan to lessen the burden of poverty, hunger and disease on the world's most vulnerable people," Inter Press Service reports.
As the covid crisis wanes and life approaches normal across the U.S., health industry leaders and many patient advocates are pushing Congress and the Biden administration to preserve the pandemic-fueled expansion of telehealth that has transformed how millions of Americans see the doctor.
› Verified 8 days ago
Dr. Joseph Thomas Backe, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1203 Medical Dr Se, Decatur, AL 35601 Phone: 256-350-2875 Fax: 256-350-6228 | |
Samantha S Wyatt, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 620 Walnut St Ne, Suite A, Decatur, AL 35601 Phone: 256-353-7775 Fax: 256-353-7765 | |
Dr. James L Reeder Sr., MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1310 Somerville Rd Se, Decatur, AL 35601 Phone: 256-350-2550 Fax: 256-350-9739 |